Is There a Role for Antiangiogenic Therapy in Renal Medullary Carcinoma? - Wikidata - awgldk - TriplyDB

Is There a Role for Antiangiogenic Therapy in Renal Medullary Carcinoma?

Is There a Role for Antiangiogenic Therapy in Renal Medullary Carcinoma?

http://www.wikidata.org/entity/Q52901669

about

Renal Medullary Carcinoma with an Aggressive Clinical Course: A Case Report and Review of the Literature.Platinum plus bortezomib for the treatment of pediatric renal medullary carcinoma: Two cases.Predictive role of PD-L1 expression in the response of renal Medullary carcinoma to PD-1 inhibition.

P2860

Q37634874-0D7BA5CA-7C40-4E5E-B7CA-B11CABC1FD8E Q40396447-356F30F6-755A-4812-829E-D46E854E5C4C Q41414590-3C82169B-DEF4-45BB-8C76-C2385A85428D

P2860

Is There a Role for Antiangiogenic Therapy in Renal Medullary Carcinoma?

http://www.wikidata.org/entity/Q52901669

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Is There a Role for Antiangiogenic Therapy in Renal Medullary Carcinoma?

@en

Is There a Role for Antiangiogenic Therapy in Renal Medullary Carcinoma?

@nl

type

label

Is There a Role for Antiangiogenic Therapy in Renal Medullary Carcinoma?

@en

Is There a Role for Antiangiogenic Therapy in Renal Medullary Carcinoma?

@nl

prefLabel

Is There a Role for Antiangiogenic Therapy in Renal Medullary Carcinoma?

@en

Is There a Role for Antiangiogenic Therapy in Renal Medullary Carcinoma?

@nl

P1433

Q52901669-0F86296D-C271-4E64-AD0A-B4DDF41FFCFE

P1476

Q52901669-825872E8-88FD-4ED3-9A28-16DE63F421D5

P2093

Q52901669-9059C5F8-2AED-4C93-A298-84AA83393F82

P2860

Q52901669-42C4A113-BB99-4C05-BC33-714AC7652F77

Q52901669-4B7151CA-0D5B-42CB-972F-1CBA27BB708F

Q52901669-66659FFF-100D-47FC-A721-69BA314B50FD

Q52901669-D31FF1CB-D111-4F7F-A580-A89CE44678C5

Q52901669-EEB8C185-D5B3-46D1-8972-8FDC49474BBC

P304

Q52901669-ABF927DE-B459-47E2-8067-D22EE45A61BE

P31

Q52901669-4ED4840B-393C-40FA-A206-ED41888260D8

P356

Q52901669-816E60FA-ED06-40C5-9F30-367FC66FBF06

P433

Q52901669-A487F313-2762-4BA4-8AF0-C2AFE8EB2878

P478

Q52901669-3721E1C0-FB7A-4DBF-B280-CB082204F55E

P577

Q52901669-3D07AE22-F0F4-4794-850F-3BAFBD1E90AB

P698

Q52901669-53B7BAF5-CF7F-41F2-BD3B-7F9D983A08BC

P356

P1433

Pediatric Blood & Cancer

P1476

Is There a Role for Antiangiogenic Therapy in Renal Medullary Carcinoma?

@en

P2093

Sandeep Batra

http://www.w3.org/2001/XMLSchema#string

P2860

Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma.

BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-A

Renal medullary carcinoma and sickle cell trait: A systematic review.

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.

P304

746-747

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PBC.25832

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26586119

http://www.w3.org/2001/XMLSchema#string